Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial

被引：87

作者：

Mathy, A

Baas, P

Dalesio, O

van Zandwijk, N

机构：

[1] Netherlands Canc Inst, Biometr Dept, NL-1066 CX Amsterdam, Netherlands

[2] Netherlands Canc Inst, Dept Thorac Oncol, NL-1066 CX Amsterdam, Netherlands

来源：

LUNG CANCER | 2005年 / 50卷 / 01期

关键词：

malignant mesothelioma; treatment; imatinib; PDGF; c-kit; anti-cancer agents;

D O I：

10.1016/j.lungcan.2005.04.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty-five patients with histologically proven malignant mesotheliorna participated in a trial of imatinib mesylate (Glivec) with a starting dose of 400mg per day taken orally, up to a maximal. dose of 800 mg. No responses were observed in the patient group, while three patients showed prolonged (> 6 months) stabilization of disease. The median survival time was 398 days (range 88-840); the median time to progression was 63 days (range 29-275). Side effects of the medication were mild and included edema, nausea, constipation and diarrhea. We conclude that further investigation with monotherapy imatinib in mesothetioma is not warranted. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：83 / 86

页数：4

共 13 条

[1] Paraffin section detection of the c-kit gene product (CD117) in human tissues:: Value in the diagnosis of mast cell disorders [J].